Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Pegcetacoplan in Geographic Atrophy (Phase 1b)
NCT03777332Phase 1Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Apr 2021
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegcetacoplan in geographic atrophy (GA) (3 cohorts), sponsored by Apellis Pharmaceuticals. Primary endpoint: Incidence and Severity of Ocular and Systemic Treatment-Emergent Adverse Events at 25 months. Started Nov 2018; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03777332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777332.